Marie N. Wong
Sydney, NSW, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Correction: Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 11, 2026
Comprehensive Multiplatform Tyrosine Kinase Profiling Reveals Novel Actionable FGFR Aberrations across Sarcomas Affecting the Young.
Journal: Molecular cancer therapeutics
Published: July 01, 2025
Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across sarcomas affecting the young.
Journal: Molecular cancer therapeutics
Published: July 01, 2025
Precision-guided therapy in H3K27-altered diffuse midline glioma.
Journal: Nature communications
Published: May 30, 2025
A novel TRKB-activating internal tandem duplication characterizes a new mechanism of receptor tyrosine kinase activation.
Journal: NPJ precision oncology
Published: November 18, 2024
Precision-guided treatment in high-risk pediatric cancers.
Journal: Nature medicine
Published: September 21, 2023
In vivo loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymoma.
Journal: Frontiers in oncology
Published: December 14, 2022
High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer.
Journal: Cancer research
Published: November 28, 2022
A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer.
Journal: Genome medicine
Published: October 13, 2022
Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes.
Journal: Scientific reports
Published: September 13, 2022
Last Updated: 09/26/2026